|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005695,
umls-concept:C0034897,
umls-concept:C0045093,
umls-concept:C0085957,
umls-concept:C0205124,
umls-concept:C0220825,
umls-concept:C0442124,
umls-concept:C0450442,
umls-concept:C1096776,
umls-concept:C1524063,
umls-concept:C1704410
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-6-6
|
|
pubmed:abstractText |
The treatment of choice for superficial bladder TCC is endoscopic resection, followed or not by intravesical immuno/chemotherapy. Some patients are not responders to common intravesical therapy and are more exposed to disease progression. In this case the suitable treatment is radical cystectomy. Because gemcitabine is effective against advanced bladder cancer, we have initiated a study to evaluate the efficacy of its intravesical use to prevent relapse and disease progression, and tolerance and safety of this drug in patients with multi-treated bladders. In this preliminary study, we cite only data on tolerance.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1124-3562
|
|
pubmed:author |
pubmed-author:CastelliEmanueleE,
pubmed-author:CasuMarilenaM,
pubmed-author:ContiGiarioG,
pubmed-author:CretarolaEmidioE,
pubmed-author:D'UrsoLeonardoL,
pubmed-author:FerrandoUgoU,
pubmed-author:GrazianoManuela EfremME,
pubmed-author:HurleRodolfoR,
pubmed-author:LanciniVanessaV,
pubmed-author:LissoniGiuseppeG,
pubmed-author:LuporiniAnna ChiaraAC,
pubmed-author:MorabitoFrancescoF,
pubmed-author:MutoGiovanniG,
pubmed-author:RazionalePasqualeP,
pubmed-author:RossiRiccardoR,
pubmed-author:SimoneMaurizioM,
pubmed-author:SommarivaMonicaM,
pubmed-author:UsIuIu
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
78
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1-4
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16752879-Adjuvants, Immunologic,
pubmed-meshheading:16752879-Administration, Intravesical,
pubmed-meshheading:16752879-Adult,
pubmed-meshheading:16752879-Aged,
pubmed-meshheading:16752879-Aged, 80 and over,
pubmed-meshheading:16752879-Antineoplastic Agents,
pubmed-meshheading:16752879-BCG Vaccine,
pubmed-meshheading:16752879-Deoxycytidine,
pubmed-meshheading:16752879-Female,
pubmed-meshheading:16752879-Humans,
pubmed-meshheading:16752879-Male,
pubmed-meshheading:16752879-Middle Aged,
pubmed-meshheading:16752879-Neoplasm Recurrence, Local,
pubmed-meshheading:16752879-Urinary Bladder Neoplasms
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: evaluation of tolerance.
|
|
pubmed:affiliation |
S C Urologia 3 D O Ospedale Molinette, Torino, Italy. dafamor@virgilio.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|
